Selection of blockbuster announcements

1. Kangfang Bio-B and Summit Therapeutics Inc. Enter into a license agreement of up to $5 billion for Ivosi (PD-1/VEGF bispecific)

$AKESO, INC. - B (09926.HK)$Announcement, on December 6, 2022, Kang Fang Bio and Summit Therapeutics Inc. (Nasdaq: SMMT) entered into a cooperation and license agreement under which Kangfang Biological will grant Summit the exclusive license to develop and commercialize its groundbreaking bispecific antibody PD-1/VEGF,AK112 in the United States, Canada, Europe and Japan. Kangfang Bio will reserve the right to develop and commercialize Ivo in areas other than those licensed by Summit. In addition, Kangfang Bio will have an interest in the co-brand of the product in the Summit licensed area. In exchange for these rights, Kang Bio received a down payment of US $500 million and a total transaction value of up to US $5 billion, including product development, registration and commercialization milestones. The company will also receive a low double-digit percentage commission on net sales of Yevosi products as royalties for the product. Together with the execution of the license agreement, Dr. Xia Yu, Chairman, Executive Director, Chief Executive Officer and President of the Company, will be appointed as a member of the Board of Directors of Summit.

2、Country Garden Holdings intends to place 1.78 billion shares at HK $2.70 per share, raising a net amount of about HK $4.741 billion

$COUNTRY GARDEN (02007.HK)$It was announced that on December 7, 2022, the company entered into a placing agreement with the placing agent, in which the company intends to place a total of 1.78 billion shares to not less than six placeholders, accounting for about 6.44% of the enlarged share capital at a price of HK $2.70 per share. The net proceeds from the placing are about HK $4.741 billion, which are proposed to be used for refinancing existing overseas debt and general working capital.

3. Shunfeng City plans to participate in the establishment of an equity investment fund, which will mainly invest in unlisted enterprises in smart, low-carbon and new opportunities for local life.

$SF INTRA-CITY (09699.HK)$Announced that the company's subsidiaries, Shenzhen Tongcheng, Zhuopu Zhiyuan, Liu Dongmei and Yang Xingyun, entered into the Xiamen Xiaoyuqingcheng Venture Capital Partnership (Limited Partnership) Partnership Agreement ("Partnership Agreement") to establish Xiamen Xiaoyuqingcheng Venture Capital Partnership (Limited Partnership) ("Fund") (subject to the final name of industrial and commercial registration), and the fund is an equity investment fund. Mainly invest in unlisted companies in smart, low-carbon and new opportunities in local life. The target size of the fund is RMB500m, of which Shenzhen City intends to contribute no more than RMB 50 million or 45 per cent of the total contribution of the fund, whichever is the lower.

4. Jianfa International Group plans to acquire 100% equity in Fujian Zhaoren with 1.562 billion yuan, so as to further expand the scale of the group's land reserve.

$C&D INTL GROUP (01908.HK)$According to the announcement, the previous announcement announced that Yiyue and Xiamen Zhaoyirong signed an equity transfer agreement with Jianfa property in Nanjing, according to which Jianfa property agreed to sell and Yiyue and Xiamen Zhaoyirong agreed to buy 95% and 5% of Jianfa Nanjing, respectively. On December 6, 2022, Yiyue and Xiamen Zhaoyirong (both indirect wholly-owned subsidiaries of the company) entered into a Fujian Zhaoren equity transfer agreement with Jianfa Real Estate and Xiamen Liyuan. Jianfa Real Estate and Xiamen Liyuan agreed to sell while Yiyue and Xiamen Zhaoyirong agreed to buy 95% and 5% of Fujian Zhaorun respectively. The total cash consideration under the Fujian Zhaorun equity transfer agreement will be RMB 10062849.77, of which Yiyue and Xiamen Zhaoyirong are required to contribute RMB 9559707.28 and RMB 503142.49 respectively. Yiyue and Xiamen Zhaoyirong are also required to repay the shareholders' loans (principal and interest) previously advanced to Fujian Zhaoren and Project Company by Yiyue and Xiamen Zhaoyirong based on the equity ratio of Yiyue and Xiamen Zhaoyirong in Fujian Zhaoren. The amount is RMB 1552127195.78. Yiyue and Xiamen Zhaoyirong will use the group's internal resources to allocate a total consideration of RMB 1562190045.55 under the Fujian Zhaoren equity transfer agreement.

5. China Overseas Land & Investment accumulated contract property sales of 256.706 billion yuan from January to November.

$China Overseas Land & Investment (00688.HK)$From January to November, cumulative contract sales totaled 256.706 billion yuan, with a total sales area of 11.8966 million square meters, down 22.1% and 28.4% respectively from the same period last year. The contract sales in November was 24.111 billion yuan, down 11.5% from the same period last year; the sales area was 1.2145 million square meters, down 12.4% from the same period last year. During the year, the total floor area attributable to the acquisition of land was about 6.3139 million square meters, and the cumulative land transfer fee was 88.142 billion yuan.

6. Tencent invested 289 million Hong Kong dollars to buy back 934400 shares on December 6.

$TENCENT (00700.HK)$In an announcement, the company bought back 934400 shares at a repurchase price of HK $307.6-HK $310.2 per share at a cost of HK $289 million on December 6, 2022.

Operation data

The total contract sales of Greentown China (03900) in the first 11 months is about 263 billion yuan.

Rongxin China (03301) had total contract sales of 56.797 billion yuan in the first 11 months.

Xiangsheng Holdings Group (02599) belongs to the Group with contract sales of 22.875 billion yuan in the first 11 months.

China Overseas Land & Investment (00688) accumulated contract property sales of 256.706 billion yuan from January to November.

China overseas Hongyang Group (00081) accumulated contract sales of 36.076 billion yuan from January to November.

Sunshine China (02608) achieved contract sales of 1.132 billion yuan in the first 11 months.

Poly Real Estate Group (00119) realized contract sales of 45 billion yuan in the first 11 months.

Zhongyuan Jianye (09982) sold 1.28 billion yuan in the contract of the management project in November.

ESR Cayman Limited (01821) spent HK $7.4556 million to buy back 450000 shares on December 6th.

The cumulative contract sales of time China Holdings (01233) in the first 11 months reached 38.201 billion yuan.

Merger and acquisition and sale

FIT HON TENG (06088) plans to sell joint venture FIT Electronics Device Pte for $14.415 million. Ltd. About 51% equity

Jianfa International Group (01908) completed the placement of 45 million shares, raising a net fund of about HK $800 million

Investment and operation

360 DigiTech Inc-S (03660) fully exercised the over-allotment option, with a net raise of HK $37.7 million

Junshi Bio (01877): completed the issuance of 70 million A-shares, raising a total of 3.7765 billion yuan

Junshi Bio (01877): plans to use no more than 3.5 billion yuan temporarily idle to raise funds for cash management

Repurchase cancellation

Tencent (00700) spent HK $289 million to buy back 934400 shares on December 6th.

AIA Group Limited (01299) spent HK $163 million to buy back 1.9612 million shares on December 6th.

CK Asset (01113) spent HK $24.0903 million to buy back 530000 shares on December 6th.

Swire AG A (00019) spent HK $17.0659 million to repurchase 285000 shares on December 6th

China Petroleum & Chemical Corporation (00386) spent HK $49.223 million to buy back 13.332 million shares on December 6th.

Lizhu Pharmaceutical (01513) spent 11.6345 million yuan to buy back 329000 A shares on December 6th.

Swire AG B (00087) spent HK $4.48 million to repurchase 480000 shares on December 6th

Kangji Medical (09997) spent HK $7.843 million to buy back 950000 shares on December 6th

Sinotrans (00598) spent HK $6.5495 million to buy back 2.561 million shares on December 6th.